Erlotinib Medical Valley
EGFR Tyrosine Kinase Inhibitor – Targeted Cancer Therapy
Quick Facts about Erlotinib Medical Valley
Key Takeaways about Erlotinib Medical Valley
- Targeted therapy: Erlotinib specifically blocks the EGFR protein, which is overactive in certain cancers, making it a more targeted treatment than traditional chemotherapy
- Take on an empty stomach: Erlotinib must be taken at least 1 hour before or 2 hours after eating, as food significantly increases absorption and may lead to increased side effects
- Skin rash may indicate effectiveness: Development of an acne-like skin rash is the most common side effect and has been associated with better treatment response in clinical studies
- Smoking reduces effectiveness: Active smoking lowers erlotinib blood levels by up to 50-65%, potentially reducing the drug's anti-cancer activity
- Regular monitoring required: Liver function tests should be performed regularly during treatment, and patients must report any new breathing difficulties immediately
What Is Erlotinib Medical Valley and What Is It Used For?
Erlotinib Medical Valley is a targeted cancer medicine (EGFR tyrosine kinase inhibitor) used primarily to treat non-small cell lung cancer (NSCLC) with activating EGFR mutations and metastatic pancreatic cancer. It works by blocking the epidermal growth factor receptor, a protein on the surface of cancer cells that promotes tumor growth.
Erlotinib belongs to a class of anti-cancer drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. The epidermal growth factor receptor is a protein found on the surface of many cells in the body, including certain cancer cells. When this receptor is activated, it sends signals inside the cell that promote growth, division, and survival. In some cancers, particularly non-small cell lung cancer, the EGFR protein is mutated or overexpressed, leading to uncontrolled cell growth.
By reversibly binding to the EGFR tyrosine kinase domain, erlotinib blocks the phosphorylation cascade that would otherwise drive tumor cell proliferation, angiogenesis (formation of new blood vessels that feed the tumor), and metastasis (spread of cancer to other parts of the body). This mechanism of action makes erlotinib fundamentally different from traditional cytotoxic chemotherapy, which kills rapidly dividing cells indiscriminately. Because erlotinib targets a specific molecular pathway, it tends to have a different and often more manageable side-effect profile compared to conventional chemotherapy.
Erlotinib Medical Valley is indicated for the following conditions:
- Non-small cell lung cancer (NSCLC): First-line treatment of patients with locally advanced or metastatic NSCLC whose tumors harbor activating EGFR mutations (such as exon 19 deletions or exon 21 L858R substitutions). It may also be used as maintenance therapy after first-line platinum-based chemotherapy in patients with stable disease, or as second- or third-line therapy after failure of at least one prior chemotherapy regimen.
- Pancreatic cancer: First-line treatment of metastatic pancreatic cancer in combination with gemcitabine. The NCCN (National Comprehensive Cancer Network) guidelines recognize this combination as a treatment option, although the clinical benefit in this setting is modest.
Before starting erlotinib for NSCLC, your oncologist will order a molecular test (such as next-generation sequencing or PCR-based assay) to determine whether your tumor carries an activating EGFR mutation. Erlotinib is most effective in patients with these specific mutations, and guidelines from the European Society for Medical Oncology (ESMO) and NCCN strongly recommend mutation testing before prescribing EGFR tyrosine kinase inhibitors.
How Does Erlotinib Work in the Body?
After oral administration, erlotinib is absorbed from the gastrointestinal tract and reaches peak blood levels approximately 4 hours after taking the tablet. The bioavailability (the fraction of the drug that reaches the bloodstream) is approximately 60% when taken on an empty stomach, but increases substantially when taken with food. This is why erlotinib must be taken on an empty stomach to ensure consistent drug levels.
Erlotinib is extensively metabolized in the liver, primarily by the CYP3A4 enzyme and to a lesser extent by CYP1A2. The elimination half-life is approximately 36 hours, which supports once-daily dosing. The drug is primarily excreted via feces (approximately 83%) with a small amount excreted in urine (approximately 8%).
Understanding erlotinib's pharmacokinetics is clinically important because many factors can alter drug levels in the body. For example, CYP3A4 inhibitors can increase erlotinib concentrations and the risk of toxicity, while CYP3A4 inducers and smoking (which induces CYP1A2) can decrease erlotinib levels and potentially reduce its effectiveness.
What Should You Know Before Taking Erlotinib Medical Valley?
Before starting erlotinib, your doctor must confirm EGFR mutation status for NSCLC, assess liver function, review all medications for interactions, and evaluate smoking status. Erlotinib is contraindicated in patients with severe hepatic impairment and must be used with extreme caution during pregnancy.
Erlotinib is a potent anti-cancer medication with significant potential side effects and drug interactions. Before beginning treatment, your oncologist will conduct a thorough evaluation to ensure the benefits outweigh the risks for your individual situation. Open communication with your healthcare team about your complete medical history, all medications (including over-the-counter drugs, herbal supplements, and vitamins), and lifestyle factors such as smoking is essential for safe treatment.
Contraindications
Erlotinib should not be used in the following situations:
- Hypersensitivity: Known allergy to erlotinib or any of the excipients (inactive ingredients) in the formulation
- Severe hepatic impairment: Patients with severely compromised liver function should not take erlotinib, as the drug is primarily metabolized by the liver and accumulation could lead to serious toxicity
Warnings and Precautions
Your healthcare team should be informed if you have or have had any of the following conditions, as special monitoring or dose adjustments may be required:
- Liver disease: Erlotinib is hepatotoxic and can cause elevations in liver enzymes (ALT, AST) and bilirubin. Liver function tests should be performed before starting treatment and periodically thereafter. Cases of hepatic failure, including fatal cases, have been reported, particularly in patients with pre-existing liver disease or those taking concurrent hepatotoxic medications.
- Lung disease: Interstitial lung disease (ILD), including fatal cases, has been reported in patients taking erlotinib. Patients should be monitored for new or worsening pulmonary symptoms such as dyspnea (shortness of breath), cough, and fever. If ILD is diagnosed, erlotinib must be discontinued immediately.
- Gastrointestinal conditions: Gastrointestinal perforation (a hole in the wall of the stomach or intestine) has been reported, sometimes fatally. Patients receiving concurrent anti-angiogenic agents, corticosteroids, NSAIDs, or those with a history of peptic ulcers or diverticular disease are at increased risk.
- Kidney disease: Cases of renal failure and renal insufficiency have been reported, including cases associated with severe dehydration from diarrhea, nausea, and vomiting. Adequate hydration is important during treatment.
- Eye problems: Corneal ulceration, perforation, and other eye disorders have been reported. Patients who develop acute or worsening eye symptoms should be referred to an ophthalmologist.
- Skin conditions: Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely. While mild-to-moderate skin rash is very common and generally manageable, severe skin reactions require treatment discontinuation.
Pregnancy and Breastfeeding
Erlotinib may cause harm to an unborn baby. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose. If you become pregnant or suspect pregnancy while taking erlotinib, inform your oncologist immediately. The decision to continue treatment must weigh the potential benefit to the mother against the risk to the fetus.
It is not known whether erlotinib is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment with erlotinib and for at least 2 weeks after the last dose.
Cases of interstitial lung disease (ILD)-like events, including fatalities, have been reported in patients receiving erlotinib. If you develop new or progressive unexplained shortness of breath, cough, or fever, contact your oncologist immediately. Erlotinib should be interrupted pending diagnostic evaluation. If ILD is confirmed, erlotinib must be permanently discontinued.
How Does Erlotinib Medical Valley Interact with Other Drugs?
Erlotinib has significant interactions with CYP3A4 inhibitors and inducers, CYP1A2 modulators, proton pump inhibitors, H2 blockers, antacids, and anticoagulants. These interactions can either increase erlotinib toxicity or reduce its anti-cancer effectiveness. Always inform your oncologist about all medications you take.
Because erlotinib is primarily metabolized by CYP3A4 and CYP1A2 enzymes in the liver, any medication that significantly affects these enzyme pathways can alter erlotinib blood levels. Additionally, erlotinib's absorption is pH-dependent, meaning drugs that change stomach acidity can reduce how much erlotinib enters the bloodstream. Understanding these interactions is critical for maintaining therapeutic drug levels and avoiding toxicity.
Major Interactions
| Drug / Drug Class | Effect on Erlotinib | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) | Increases erlotinib levels (AUC increased by ~67% with ketoconazole) | Avoid combination if possible; if unavoidable, reduce erlotinib dose and monitor closely for toxicity |
| Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John's wort) | Dramatically decreases erlotinib levels (AUC reduced by ~69% with rifampicin) | Avoid combination; use alternative medications that do not induce CYP3A4 |
| Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole) | Reduces erlotinib absorption by decreasing gastric acidity (AUC reduced by ~46%) | Avoid combination; if acid suppression is needed, use antacids separated by several hours |
| Warfarin and coumarin anticoagulants | Erlotinib may increase anticoagulant effect; elevated INR and bleeding events reported | Monitor INR frequently; consider switching to low-molecular-weight heparin |
| CYP1A2 inhibitors (ciprofloxacin, fluvoxamine) | Increases erlotinib levels by inhibiting secondary metabolic pathway | Use with caution; monitor for increased side effects |
Minor Interactions
Several other medications have less clinically significant but still noteworthy interactions with erlotinib:
- H2 receptor antagonists (ranitidine, famotidine): These reduce erlotinib absorption, though less than PPIs. If used, erlotinib should be taken at least 2 hours before or 10 hours after the H2 blocker.
- Antacids (aluminum/magnesium hydroxide): Should be separated from erlotinib by several hours to minimize impact on absorption.
- Statins: Erlotinib may increase levels of certain statins metabolized by CYP3A4, potentially increasing the risk of muscle-related side effects.
- Tobacco smoke: While not a drug interaction per se, cigarette smoking induces CYP1A2 and reduces erlotinib exposure by 50-65%. Patients should be strongly encouraged to stop smoking before and during treatment.
Always provide your oncologist with a complete list of all prescription medications, over-the-counter drugs, herbal supplements (especially St. John's wort), and vitamins you are taking. Even seemingly harmless supplements or antacids can significantly affect erlotinib's effectiveness. Never start, stop, or change the dose of any medication without consulting your oncologist first.
What Is the Correct Dosage of Erlotinib Medical Valley?
The standard dose of erlotinib for NSCLC is 150 mg once daily and for pancreatic cancer is 100 mg once daily (combined with gemcitabine). The tablet should be taken on an empty stomach, at least 1 hour before or 2 hours after food. Dose reductions in 50 mg decrements may be needed for side effects.
Erlotinib Medical Valley is available as 25 mg film-coated tablets. The prescribing oncologist will determine the appropriate number of tablets based on the indicated dose, which varies depending on the type of cancer being treated. It is critically important to take erlotinib exactly as prescribed by your oncologist. Never change your dose without medical advice, even if you experience side effects.
Adults
| Indication | Standard Dose | Timing | Notes |
|---|---|---|---|
| NSCLC (first-line, EGFR mutation-positive) | 150 mg once daily | At least 1 hour before or 2 hours after meals | Continue until disease progression or unacceptable toxicity |
| NSCLC (maintenance or subsequent lines) | 150 mg once daily | At least 1 hour before or 2 hours after meals | Monotherapy after failure of prior chemotherapy |
| Pancreatic cancer | 100 mg once daily | At least 1 hour before or 2 hours after meals | In combination with gemcitabine |
If dose reduction is necessary due to side effects, the dose should be reduced in 50 mg decrements (e.g., from 150 mg to 100 mg, or from 100 mg to 50 mg). The 25 mg tablet strength is available for precise dose adjustments and for patients requiring lower doses.
Children
The safety and efficacy of erlotinib in pediatric patients (under 18 years of age) have not been established. Erlotinib is not recommended for use in children and adolescents. Pediatric oncology treatment decisions should be made by specialized pediatric oncologists in consultation with the family.
Elderly
No specific dose adjustment is recommended for elderly patients based on age alone. However, elderly patients may be more susceptible to certain side effects, particularly dehydration from diarrhea, skin toxicity, and hepatotoxicity. Careful monitoring and proactive management of side effects are important in this population. Renal and hepatic function should be assessed before starting treatment, as age-related decline in organ function is common.
Missed Dose
If you miss a dose of erlotinib, take it as soon as you remember, provided it is still well before your next scheduled dose. If it is nearly time for the next dose, skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed one. If you frequently forget doses, discuss strategies with your healthcare team, as consistent dosing is important for maintaining therapeutic drug levels.
Overdose
There is limited clinical experience with overdose of erlotinib. In clinical trials, single doses up to 1,000 mg and repeated doses up to 200 mg twice daily have been studied. Symptoms of overdose may include severe diarrhea, severe skin rash, and liver enzyme elevations. There is no specific antidote for erlotinib overdose. Treatment is supportive and symptomatic. If you suspect an overdose, contact your local poison control center or emergency services immediately.
Always take erlotinib on an empty stomach, at least 1 hour before or 2 hours after eating. Taking erlotinib with food substantially increases its absorption and blood levels, which may lead to increased side effects. Swallow the tablet whole with water. Do not crush, chew, or break the tablet.
What Are the Side Effects of Erlotinib Medical Valley?
The most common side effects of erlotinib include acne-like skin rash (affecting over 50% of patients), diarrhea, fatigue, decreased appetite, and nausea. Serious but less common side effects include interstitial lung disease, liver toxicity, gastrointestinal perforation, and severe skin reactions. Skin rash development has been correlated with better treatment outcomes.
Like all medicines, erlotinib can cause side effects, although not everybody gets them. The side effect profile of erlotinib is distinct from traditional chemotherapy because it targets a specific molecular pathway rather than all rapidly dividing cells. Understanding the expected side effects, their frequency, and when to seek medical attention is important for managing your treatment effectively.
An important clinical observation is that the development of skin rash during erlotinib treatment has been consistently associated with improved survival outcomes in multiple clinical trials. This correlation, while not fully understood, means that skin rash, though uncomfortable, may be a positive indicator of drug activity. Your oncology team can help manage skin side effects to allow you to continue treatment.
Very Common (affects more than 1 in 10 patients)
- Skin rash (acne-like, predominantly on face, upper chest, and back)
- Diarrhea
- Fatigue and asthenia (weakness)
- Decreased appetite and weight loss
- Nausea
- Dry skin (xerosis)
- Pruritus (itching)
- Stomatitis (mouth sores)
- Abdominal pain
- Infections (including skin infections related to rash)
- Conjunctivitis and keratoconjunctivitis sicca (dry eyes)
Common (affects 1 in 10 to 1 in 100 patients)
- Vomiting
- Dyspepsia (indigestion)
- Flatulence
- Paronychia (nail bed infections)
- Alopecia (hair loss or thinning)
- Nosebleeds (epistaxis)
- Elevated liver enzymes (ALT, AST)
- Depression
- Neuropathy (tingling or numbness)
- Headache
- Cough and dyspnea (shortness of breath)
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
- Interstitial lung disease (ILD) / pneumonitis
- Hepatic failure and severe hepatotoxicity
- Gastrointestinal perforation
- Renal failure
- Corneal ulceration or perforation
- Severe skin reactions (erythema multiforme)
- Hypokalemia (low potassium)
Rare (affects fewer than 1 in 1,000 patients)
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Microangiopathic hemolytic anemia with thrombocytopenia
- Cerebrovascular accident (stroke)
Contact your oncologist or seek emergency care immediately if you experience any of the following:
- New or worsening shortness of breath, cough, or fever (possible interstitial lung disease)
- Severe or persistent diarrhea, nausea, or vomiting leading to dehydration
- Yellowing of the skin or eyes, dark urine, or severe abdominal pain (possible liver toxicity)
- Severe abdominal pain, especially with fever (possible gastrointestinal perforation)
- Severe skin blistering or peeling (possible Stevens-Johnson syndrome)
- Eye pain, redness, or vision changes
Managing Common Side Effects
Many of erlotinib's common side effects can be effectively managed with supportive care, allowing patients to continue treatment:
- Skin rash: Use gentle, fragrance-free cleansers and moisturizers. Apply sunscreen (SPF 30+) daily. Your doctor may prescribe topical or oral antibiotics for moderate-to-severe rash. Avoid hot showers and alcohol-based products on the skin.
- Diarrhea: Stay well-hydrated with clear fluids. Your doctor may recommend loperamide (an over-the-counter anti-diarrheal medication) for mild-to-moderate cases. Severe or persistent diarrhea requires medical evaluation.
- Dry skin: Apply thick, emollient moisturizers (such as those containing urea or ceramides) multiple times daily. Avoid long, hot baths or showers.
- Mouth sores: Practice good oral hygiene. Avoid spicy, acidic, or very hot foods. Use alcohol-free mouthwash. Your doctor may prescribe a specialized oral rinse.
How Should You Store Erlotinib Medical Valley?
Store Erlotinib Medical Valley below 25°C (77°F) in the original packaging to protect from moisture and light. Keep out of reach of children. Do not use after the expiry date printed on the packaging. Return unused or expired medication to a pharmacy for safe disposal.
Proper storage of erlotinib is important to ensure the medication remains effective throughout its shelf life. Incorrect storage conditions can degrade the active ingredient, potentially reducing the drug's effectiveness or leading to harmful breakdown products.
Follow these storage guidelines carefully:
- Store at temperatures below 25°C (77°F). Do not refrigerate or freeze.
- Keep the tablets in the original blister packaging until ready to take, to protect from moisture and light.
- Do not store in the bathroom or other humid environments.
- Keep out of the sight and reach of children. Erlotinib is a cytotoxic medication and accidental ingestion by children could be extremely dangerous.
- Do not use this medicine after the expiry date stated on the carton and blister after "EXP." The expiry date refers to the last day of that month.
- Do not throw away any medicines via household waste or wastewater. Return unused or expired tablets to your pharmacist for safe disposal. These measures help protect the environment from cytotoxic contamination.
Erlotinib is a cytotoxic (anti-cancer) medicine. While the film coating provides a barrier during normal handling, it is advisable to wash your hands after handling the tablets. If a tablet is accidentally crushed or broken, avoid inhaling the dust or getting it on your skin. If skin contact with crushed tablet material occurs, wash the area thoroughly with soap and water.
What Does Erlotinib Medical Valley Contain?
Each Erlotinib Medical Valley 25 mg film-coated tablet contains 25 mg of erlotinib (as erlotinib hydrochloride) as the active ingredient, along with inactive excipients including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients.
Active substance: Each film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride). Erlotinib hydrochloride is the salt form used in the formulation because of its superior stability and dissolution properties compared to the free base.
Tablet core excipients (inactive ingredients):
- Lactose monohydrate (a filler/bulking agent)
- Microcrystalline cellulose (a binder and filler)
- Sodium starch glycolate (a disintegrant to help the tablet break down)
- Sodium lauryl sulfate (a wetting agent to improve dissolution)
- Magnesium stearate (a lubricant for tablet manufacturing)
Film coating:
- Hypromellose (hydroxypropyl methylcellulose, a film-forming agent)
- Titanium dioxide (E171, a white colorant)
- Macrogol/polyethylene glycol (a plasticizer for the coating)
This medicine contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. The amount of lactose per tablet is small, but patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Frequently Asked Questions about Erlotinib Medical Valley
References
All medical information on this page is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Erlotinib - Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Erlotinib - Prescribing Information. Available at: www.fda.gov. Accessed January 2026.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2026.
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132. doi:10.1056/NEJMoa050753
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2007;25(15):1960-1966. doi:10.1200/JCO.2006.07.9525
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). Lancet Oncol. 2012;13(3):239-246. doi:10.1016/S1470-2045(11)70393-X
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Ann Oncol. 2023.
- British National Formulary (BNF). Erlotinib monograph. Available at: bnf.nice.org.uk. Accessed January 2026.
- World Health Organization (WHO). WHO Model List of Essential Medicines - 23rd List, 2023. Geneva: World Health Organization; 2023.
- Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913-3921.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in oncology, clinical pharmacology, and pharmaceutical sciences.
Written by licensed physicians specializing in oncology and clinical pharmacology. All content follows international treatment guidelines (NCCN, ESMO, EMA, FDA).
Independently reviewed by the iMedic Medical Review Board. Evidence level 1A based on systematic reviews of randomized controlled trials and international guidelines.
Last medical review: . Next scheduled review: .